2 false false false false false false false false false false true false false false false false false No description of principal activity 2025-02-01 Sage Accounts Production Advanced 2024 - FRS102_2024 958 175 1,133 160 218 378 755 798 xbrli:pure xbrli:shares iso4217:GBP 15400366 2025-02-01 2026-01-31 15400366 2026-01-31 15400366 2025-01-31 15400366 2024-01-09 2025-01-31 15400366 2025-01-31 15400366 2024-01-08 15400366 bus:Director2 2025-02-01 2026-01-31 15400366 core:WithinOneYear 2026-01-31 15400366 core:WithinOneYear 2025-01-31 15400366 core:SharePremium 2026-01-31 15400366 core:OtherReservesSubtotal 2025-01-31 15400366 core:RetainedEarningsAccumulatedLosses 2026-01-31 15400366 core:RetainedEarningsAccumulatedLosses 2025-01-31 15400366 bus:Director1 2025-02-01 2026-01-31 15400366 bus:SmallEntities 2025-02-01 2026-01-31 15400366 bus:AuditExemptWithAccountantsReport 2025-02-01 2026-01-31 15400366 bus:SmallCompaniesRegimeForAccounts 2025-02-01 2026-01-31 15400366 bus:PrivateLimitedCompanyLtd 2025-02-01 2026-01-31 15400366 bus:FullAccounts 2025-02-01 2026-01-31 15400366 core:OfficeEquipment 2025-02-01 2026-01-31 15400366 core:OfficeEquipment 2025-01-31 15400366 core:OfficeEquipment 2026-01-31
COMPANY REGISTRATION NUMBER: 15400366

Greenleaf Bio Ltd

Filleted Unaudited Financial Statements

31 January 2026

Greenleaf Bio Ltd

Financial Statements

Year ended 31 January 2026

Contents | Page

Statement of financial position | 1

Notes to the financial statements | 3

Greenleaf Bio Ltd

Statement of Financial Position

31 January 2026

| 2026 | 2025
Note | £ | £

Fixed assets

Tangible assets | 6 | 755 | 798

Current assets

Debtors | 7 | 39,869 | 12,191
Cash at bank and in hand | 620,957 | 191,814
| --------- | ---------
| 660,826 | 204,005

Creditors: amounts falling due within one year | 8 | 7,495 | 43,146
| --------- | ---------
Net current assets | 653,331 | 160,859
| --------- | ---------
Total assets less current liabilities | 654,086 | 161,657
| --------- | ---------
Net assets | 654,086 | 161,657
| --------- | ---------

Capital and reserves

Share premium account | 930,813 | –
SAFE | – | 239,259
Profit and loss account | ( 276,727) | ( 77,602)
| --------- | ---------
Shareholders funds | 654,086 | 161,657
| --------- | ---------

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
For the year ending 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

Greenleaf Bio Ltd

Statement of Financial Position (continued)

31 January 2026
These financial statements were approved by the board of directors and authorised for issue on 6 July 2026 , and are signed on behalf of the board by:

Dr G M Taylor
Director

Company registration number: 15400366

Greenleaf Bio Ltd

Notes to the Financial Statements

Year ended 31 January 2026
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Camburgh House, 27 New Dover Road, Canterbury, Kent, CT1 3DN, United Kingdom.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively.
Foreign currencies
Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the profit and loss account.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

| Equipment | - | 20% straight line

Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.
Financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses. Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently, they are measured at amortised cost using the effective interest rate method, less impairment. If an arrangement constitutes a finance transaction it is measured at present value.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 2 (2025: 2 ).
5. Share capital
The company has issued 20,000 ordinary shares at par giving a share capital total at £0.02.
The company has issued 6,221 preferred shares at par giving a share capital total at £0.006221.
Therefore, the total share capital issued is £0.26221.
Due to the rounding factor the accounts have been prepared with, the balance sheet does not show any share capital.
6. Tangible assets

| Equipment
| £
Cost |
At 1 February 2025 | 958
Additions | 175
| -------
At 31 January 2026 | 1,133
| -------
Depreciation |
At 1 February 2025 | 160
Charge for the year | 218
| -------
At 31 January 2026 | 378
| -------
Carrying amount |
At 31 January 2026 | 755
| -------
At 31 January 2025 | 798
| -------

7. Debtors

| 2026 | 2025
| £ | £
Other debtors | 39,869 | 12,191
| -------- | --------

8. Creditors: amounts falling due within one year

| 2026 | 2025
| £ | £
Trade creditors | 1,919 | 115
Other creditors | 5,576 | 43,031
| ------- | --------
| 7,495 | 43,146
| ------- | --------